These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17923462)

  • 1. The impact of pre-hospital thrombolytic treatment on re-infarction rates: analysis of the Myocardial Infarction National Audit Project (MINAP).
    Horne S; Weston C; Quinn T; Hicks A; Walker L; Chen R; Birkhead J
    Heart; 2009 Apr; 95(7):559-63. PubMed ID: 17923462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East.
    Al-Zakwani I; Ali A; Zubaid M; Panduranga P; Sulaiman K; Abusham A; Almahmeed W; Al-Motarreb A; Al Suwaidi J; Amin H
    J Thromb Thrombolysis; 2012 Apr; 33(3):280-6. PubMed ID: 22359050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prehospital administration of tenecteplase for ST-segment elevation myocardial infarction in a rural EMS system.
    Crowder JS; Hubble MW; Gandhi S; McGinnis H; Zelman S; Bozeman W; Winslow J
    Prehosp Emerg Care; 2011; 15(4):499-505. PubMed ID: 21815730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2.
    Gupta M; Chang WC; Van de Werf F; Granger CB; Midodzi W; Barbash G; Pehrson K; Oto A; Toutouzas P; Jansky P; Armstrong PW;
    Eur Heart J; 2003 Sep; 24(18):1640-50. PubMed ID: 14499226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety comparison between pro-urokinase and reteplase in the treatment of patients with acute ST elevation myocardial infarction].
    Zhang Y; Wang S; Gao CY; Liu XY; Cheng QQ; Zhang JH; Qi DD; Wang XP; Zhu ZY; Li MW; Hu DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Sep; 49(9):866-872. PubMed ID: 34530593
    [No Abstract]   [Full Text] [Related]  

  • 6. Spotlight on reteplase in thrombotic occlusive disorders.
    Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
    BioDrugs; 2007; 21(1):65-8. PubMed ID: 17263591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biochemical predictors affect the choice and the short-term outcomes of different thrombolytic agents in acute myocardial infarction.
    El-Menyar AA; Altamimi OM; Gomaa MM; Dabdoob W; Abbas AA; Abdel Rahman MO; Bener A; Albinali HA
    Coron Artery Dis; 2006 Aug; 17(5):431-7. PubMed ID: 16845251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of in-hospital mortality for patients admitted with ST-elevation myocardial infarction: a real-world study using the Myocardial Infarction National Audit Project (MINAP) database.
    Gale CP; Manda SO; Batin PD; Weston CF; Birkhead JS; Hall AS
    Heart; 2008 Nov; 94(11):1407-12. PubMed ID: 18070941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facilitated percutaneous coronary intervention (PCI) in patients with acute ST-elevation myocardial infarction: comparison of prehospital tirofiban versus fibrinolysis before direct PCI.
    Möckel M; Bocksch W; Strohm S; Kühnle Y; Vollert J; Nibbe L; Dietz R
    Int J Cardiol; 2005 Aug; 103(2):193-200. PubMed ID: 16080980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy).
    Cura FA; Roffi M; Pasca N; Wolski KE; Lincoff AM; Topol EJ; Lauer MS;
    Am J Cardiol; 2004 Oct; 94(7):859-63. PubMed ID: 15464665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reteplase: a review of its use in the management of thrombotic occlusive disorders.
    Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
    Am J Cardiovasc Drugs; 2006; 6(4):265-85. PubMed ID: 16913828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tenecteplase in ST elevation myocardial infarction patients from the Elaxim Indian Registry.
    Iyengar SS; Nair T; Sathyamurthy I; Hiremath JS; Jadhav U; Kumbla D; Jain RK; Srinivasan M; Sahoo PK; Chawla K; Katiyal VK
    Indian Heart J; 2009; 61(5):480-1. PubMed ID: 20635768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and timing of prehospital administration of reteplase in patients with acute myocardial infarction.
    Rosenberg DG; Levin E; Lausell A; Brown A; Gardner J; Perez E; Veenendaal M; Ong YS; Gunn M
    J Thromb Thrombolysis; 2002 Jun; 13(3):147-53. PubMed ID: 12355031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of thrombolytic therapy using reteplase in cases with acute ST-segment elevation myocardial infarction: results from a multicenter clinical trial].
    Liu XY; Zhang Y; Li MW; Wang XP; Qi DD; Hao PY; Zhang H; Cheng QQ; Zhao LS; Gao CY; Hu DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Sep; 44(9):766-770. PubMed ID: 27667274
    [No Abstract]   [Full Text] [Related]  

  • 16. Tenecteplase in the treatment of acute myocardial infarction.
    Chandra KS; Jariwala P; Lathi P
    Indian Heart J; 2009; 61(5):437-42. PubMed ID: 20635758
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3).
    Curtis JP; Alexander JH; Huang Y; Wallentin L; Verheugt FW; Armstrong PW; Krumholz HM; Van de Werf F; Danays T; Cheeks M; Granger CB;
    Am J Cardiol; 2004 Aug; 94(3):279-83. PubMed ID: 15276088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bolus fibrinolytic therapy in acute myocardial infarction.
    Llevadot J; Giugliano RP; Antman EM
    JAMA; 2001 Jul; 286(4):442-9. PubMed ID: 11466123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI).
    Di Mario C; Bolognese L; Maillard L; Dudek D; Gambarati G; Manari A; Guiducci V; Patrizi G; Rusconi LC; Piovaccari G; Hibon AR; Belpomme V; Indolfi C; Olivari Z; Steffenino G; Zmudka K; Airoldi F; Panzarasa R; Flather M; Steg PG
    Am Heart J; 2004 Sep; 148(3):378-85. PubMed ID: 15389222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.
    Wallentin L; Goldstein P; Armstrong PW; Granger CB; Adgey AA; Arntz HR; Bogaerts K; Danays T; Lindahl B; Mäkijärvi M; Verheugt F; Van de Werf F
    Circulation; 2003 Jul; 108(2):135-42. PubMed ID: 12847070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.